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ORIGINAL ARTICLE
The focal adhesion-associated proteins DOCK5 and GIT2
comprise a rheostat in control of epithelial invasion
SR Frank1, CP Köllmann1, JF van Lidth de Jeude1, JR Thiagarajah1, LH Engelholm2, M Frödin3 and SH Hansen1
DOCK proteins are guanine nucleotide exchange factors for Rac and Cdc42 GTPases. DOCK1 is the founding member of the family
and acts downstream of integrins via the canonical Crk-p130Cas complex to activate Rac GTPases in numerous contexts. In contrast,
DOCK5, which possesses the greatest similarity to DOCK1, remains sparingly studied. Here we establish that DOCK5 has a non-
redundant role in regulating motile and invasive capacities of epithelial cells. DOCK1 is constitutively associated with sites of
integrin attachment termed focal adhesions (FAs). In contrast, we demonstrate that DOCK5 recruitment to FAs in Hela cells is
restricted by GIT2, an established regulator of FA signaling. We determine that GIT2 is targeted to FAs in response to Rho-ROCK
signaling and actomyosin contractility. Accordingly, inhibition of ROCK activity or MLC function promotes enrichment of DOCK5 in
membrane protrusions and nascent cell–substratum adhesions. We further demonstrate that GIT2 inhibits the interaction of DOCK5
with Crk. Moreover, we show that depletion of GIT2 promotes DOCK5-dependent activation of the Crk-p130Cas signaling cascade
to promote Rac1-mediated lamellipodial protrusion and FA turnover. The antagonism between GIT2 and DOCK5 extends to non-
transformed MCF10A mammary epithelial cells, with DOCK5 ‘dialing-up’ and GIT2 ‘dialing-down’ invasiveness. Finally, we determine
that DOCK5 inhibition attenuates invasion and metastasis of MDA-MB-231 cells and prolongs life span of mice injected with these
cells. Collectively, our work identiﬁes DOCK5 as a key regulator of epithelial invasion and metastasis, and demonstrates that
suppression of DOCK5 by GIT2 represents a previously unappreciated mechanism for coordination of Rho and Rac GTPases.
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INTRODUCTION
Cell motility requires coordinated actin polymerization and cell
adhesion. Directional cell motility moreover necessitates the
establishment of front-to-back cell polarity with a protrusive
leading edge and a retractive trailing edge. At the leading edge,
nascent cell–matrix adhesions tether membrane protrusions to
the substrate, whereas mature adhesions behind the leading edge
ﬁrmly attach the cell membrane to actin stress ﬁbers. These front
and rear domains are regulated by Rac and RhoA GTPases,
respectively. Moreover, Rac and RhoA antagonize each other, thus
reinforcing polarized activation of these GTPases at distinct
regions of the cell.1
Activation of Rho GTPases relies on guanine nucleotide
exchange factors (GEFs) to promote exchange of GDP for GTP.
More than 80 RhoGEFs exist, thus underscoring the precise
spatiotemporal control of Rho activation in cell motility.2 The
DOCK family comprises 11 GEFs, which are frequently referred to
as ‘atypical’ to distinguish them from the larger Dbl family.2 DOCKs
are classiﬁed into four subgroups all characterized by the presence
of two evolutionarily conserved DOCK homology region (DHR)
domains: the lipid-binding DHR-1 and the catalytic DHR-2.3,4
The DOCK-A branch comprises DOCK1, DOCK2 and DOCK5,
which function as Rac-speciﬁc GEFs.2 DOCK-A members also
possess a proline-rich carboxy-terminal domain that binds to the
SH2-SH3 adaptor molecule Crk, which mediates targeting to focal
adhesions (FAs).5,6 Assembly of a Crk-p130Cas-DOCK1 complex
promotes Rac activation in response to integrin engagement.7
Numerous studies have linked DOCK1 to cellular processes that
require coordinated cell adhesion and actin remodeling, such as
axon guidance, myoblast fusion, apoptotic cell engulfment and
cell migration.2 Recently, oncogenic signaling pathways were
demonstrated to regulate DOCK1 activity through phosphoryla-
tion, implicating DOCK1 as a key factor in transformation and
metastasis.8,9 DOCK2 is predominantly expressed in hematopoietic
tissues where it regulates chemotactic migration and lymphocyte
trafﬁcking.10
DOCK5 is the least studied member of the DOCK family, perhaps
as result of a dispensable role in murine gross embryonic
development and an apparently redundant role in cell
migration.11,12 DOCK5-deﬁcient mice exhibit increased bone mass
because of a requirement for DOCK5 in osteoclast adhesion.13
In addition, DOCK5 promotes myoblast fusion, mast cell degra-
nulation and neutrophil chemotaxis.14,15 Here we identify a role
for DOCK5 in epithelial cell motility and invasion. Mechanistically,
we show that the FA-associated protein GIT2 suppresses interac-
tion of Crk with DOCK5, thus preventing activation of a Crk-
p130Cas-DOCK5 signaling cascade required for plasma membrane
protrusion and FA turnover. Moreover, our data indicate that the
inhibitory activity of GIT2 requires Rho- and tension-dependent
targeting to cell–matrix adhesions. Furthermore, we demonstrate
that GIT2 and DOCK5 function as a rheostat in control of invasive
capacities in the non-transformed mammary epithelial cell line
MCF10A. Finally, we show that in the invasive breast cancer line
MDA-MB-231, depletion of DOCK5 attenuates invasiveness result-
ing in reduced tumor burden and increased survival time in mice
challenged intravenously with these cells.
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RESULTS
GIT2 represses DOCK5 function
GIT2 is targeted to FAs via its association with paxillin, where it has
an important role in regulating cell motility.16 Along with others,
our group have found that GIT2 functions to restrict the function
of Rac, as loss of GIT2, or its paralog GIT1, results in deregulated
Rac signaling in numerous cell types.17–21
We previously reported that GIT2 suppresses Crk-dependent
lamellipodial protrusion.19 The Crk adaptor protein is a constituent
of the canonical paxillin-Crk-p130Cas-DOCK1 signaling module
required for Rac activation. We hypothesized that DOCK1 may be
a target of GIT2 repression.5–7 To test this hypothesis, GIT2 was
depleted alone or in combination with DOCK1 (Supplementary
Figure S1a). Surprisingly, DOCK1 is not required for cell spreading
induced by GIT2-kd (Supplementary Figure S1b). As DOCK5 is the
most closely related protein to DOCK1, we speculated that GIT2
may modulate the function of DOCK5 instead. We generated a
highly speciﬁc antiserum against the divergent C-terminal tail of
DOCK5 (Supplementary Figure S1c). Using this antiserum, we
determined that DOCK5 is readily detected in numerous cell lines,
including HeLa cells (Supplementary Figure S1d). Next, DOCK5
was targeted alone or together with GIT2 by short hairpin RNA
(shRNA)-mediated gene silencing (Supplementary Figure S1a).
Depletion of DOCK5 completely abrogates enhanced membrane
protrusiveness (Figure 1a) and cell spreading (Figure 1b and
Supplementary Figure S1b) elicited by GIT2-kd. These effects were
reproduced with an additional four shRNAs targeting distinct
sequences in the DOCK5 message (Supplementary Figures S2a–c).
Furthermore, in HeLa cells, knockdown of DOCK5 alone inhibits
lamellipodial extension and cell spreading (Figures 1a and b), as
well as cell adhesion (Figure 1c).
HeLa cells express Rac1 and Rac3. To identify the Rac form,
which GIT2 represses, we depleted GIT2 together with Rac1 or
Rac3. Rac1-kd effectively abrogates cell spreading elicited by
GIT2 depletion, whereas Rac3-kd has no effect (Figure 1d).
To determine the effects of GIT2 and/or DOCK5 depletion on
the subcellular localization of activated Rac, we stained HeLa cells
with an antibody speciﬁc for the GTP-bound form of Rac
(Figure 1e). The staining revealed strong enrichment in peripheral
membrane rufﬂes elicited by knockdown of GIT2 (Figure 1e). Such
staining was also observed to a lesser extent in control cells, but
never in cells depleted of DOCK5 alone or in combination with
GIT2 (Figure 1f).
Next, to establish whether GIT2- and DOCK5-modulated
changes in lamellipodial protrusion and cell spreading were
associated with altered FA turnover, we generated Hela cells
expressing paxillin-green ﬂuorescent protein (GFP) and performed
live cell imaging (Figure 1g). Depletion of GIT2 in these cells elicits
strong increases in the rates of FA assembly, disassembly and
turnover that are abrogated by DOCK5-kd (Figure 1h). Moreover,
depletion of DOCK5 alone reduces these rates signiﬁcantly relative
control cells (Figure 1h).
Engagement of integrins activates the tyrosine kinases FAK and
Src, which phosphorylate paxillin on Y31 and Y118, thereby
facilitating binding of Crk and assembly of the Crk-p130Cas-
DOCK1 complex.17,22–24 We therefore tested a possible role for
GIT2 in regulation of this signaling cascade. Knockdown of GIT2
enhances phosphorylation of paxillin at Y118 and p130Cas at Y410
(Figures 2a and b). GIT2-kd also promotes autophosphorylation of
FAK at Y397 (Figures 2a and b). DOCK5 appears to be a key
activator of this pathway, as DOCK5-deﬁcient cells show impaired
phosphorylation of p130Cas, paxillin and FAK (Figures 2a and b).
Importantly, DOCK5 is essential for the induced phosphorylation
of these proteins in response to GIT2-kd (Figures 2a and b).
To determine if GIT2 modulates the interaction between Crk and
DOCK5 and/or p130Cas, we conducted co-immunoprecipitation
assays with anti-Crk antibody. Knockdown of GIT2 elicited a
signiﬁcant increase in the interaction between DOCK5 and
Crk without affecting the association of p130Cas and Crk
(Figures 2c and d). Next, to test a requirement for the interaction
between DOCK5 and Crk in promoting cell spreading, we expressed
a Myc-tagged form of the DOCK5 Crk-binding domain (DOCK5-CBD;
amino acids 1712–1871), which would be expected to act as a
dominant inhibitory molecule. Although low level expression of
DOCK5-CBD alone exerts minor effects on control cells, there is a
signiﬁcant reduction of cell spreading in GIT2-depleted cells
(Figures 2e and f). Collectively, the data support a role for GIT2 as
a suppressor of a Crk-p130Cas-DOCK5 signaling pathway in control
of FA dynamics and Rac1-regulated cell motility. Moreover, these
results establish that DOCK5 has an essential and non-redundant role
in membrane protrusiveness at the cell periphery.
Localization of DOCK5 is controlled by GIT2
To elucidate how GIT2 may regulate DOCK5 function we examined
the localization of exogenous DOCK1 and DOCK5 in HeLa cells.
Although DOCK1 constitutively localizes to FAs (Figure 3a), DOCK5
is found in discrete structures that closely surround but do not
overlap with FAs (Figure 3a). In spreading control cells, exogenous
DOCK5 was localized peripheral to paxillin-enriched FAs. In
contrast, we observed robust colocalization of DOCK5 with paxillin
in FAs of spreading GIT2-kd cells (Figure 3b). These results show
that GIT2 restricts access of DOCK5 to FAs.
We next examined the localization of endogenous DOCK5 in
spreading HeLa cells. In control cells, DOCK5 is located at the tip of
cellular protrusions (Figure 3c). Strikingly, GIT2-kd enhances
membrane recruitment of DOCK5 and colocalization with paxillin
at the cell periphery (Figure 3c). Interestingly, DOCK5-depleted
cells exhibit fewer and much larger FAs, that is, the direct opposite
of what is observed upon GIT2 knockdown (Figure 3c).
Our ﬁndings indicated that activation of a Crk-p130Cas-DOCK5
signaling pathway in response to GIT2 depletion promotes Rac1
activation at the cell periphery. Our DOCK5 and Rac-GTP
antibodies require denaturing and non-denaturing ﬁxation,
respectively. Therefore, to determine whether endogenous DOCK5
was speciﬁcally associated with Rac-regulated lamellipodia, we
localized Arp3, which operates downstream of Rac to promote
actin polymerization. In control cells, DOCK5 and Arp3 colocalize
in isolated membrane protrusions at the cell periphery (Figure 3d).
Depletion of GIT2 results in a marked enhancement of Arp3 at the
cell periphery where Arp3 associates with DOCK5-labeled
lamellipodia (Figure 3d). Importantly, DOCK5 is required for
generation of Arp3-rich membrane protrusions in response to
GIT2 knockdown (Figure 3d). These results are consistent with a
role for GIT2 in limiting DOCK5-dependent activation of Rac1 at
the cell periphery.
DOCK5 is regulated by a Rho-modulated signaling cascade
In motile cells, Rac and Rho antagonize each other’s activities to
mediate polarized assembly of the actin cytoskeleton.1
We previously demonstrated that endogenous GIT2 localizes to
Rho-stabilized FAs.19 Taken together with our present data, it
raises the possibility that DOCK5 is regulated in a Rho-dependent
manner. To test this hypothesis, we treated cells with the myosin II
inhibitor blebbistatin, which inhibits Rho-dependent cell retraction
and causes rapid disassembly of FAs. Moreover, inhibition of
actomyosin contractility activates Rac-dependent membrane
extension but the mechanism by which tension inhibits Rac is
not well deﬁned.1
HeLa cells show enhanced membrane protrusion in the
presence of blebbistatin (Figure 4a). In contrast, treatment of
DOCK5-kd cells with blebbistatin results in cell collapse (Figure 4a).
Blebbistatin causes the disassembly of mature FAs and the
redistribution of paxillin to small adhesions located throughout
the cell (Figure 4b). At later times, paxillin can be observed in
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nascent complexes concentrated at the protrusive edge of the cell
(Figure 4b). There is marked enrichment of DOCK5 in lamellipodia
of blebbistatin-treated cells, where it colocalizes with paxillin and
Arp3 (Figures 4b and c). In stably adherent cells, DOCK5 depletion
elicits a substantial increase in FA size, again implicating DOCK5 in
FA turnover (Figure 4b). Similar to control cells, blebbistatin
treatment of DOCK5-kd cells results in FA disassembly and paxillin
redistribution. However, in contrast to control cells, DOCK5-kd
cells fail to assemble membrane protrusions with nascent
adhesions (Figure 4b). Moreover, DOCK5-depleted cells exhibit
an inability to maintain p130Cas phosphorylation in the presence
of blebbistatin, which supports a requirement for DOCK5 in
activation of the Crk-p130Cas signaling pathway (Figure 4d).
Blebbistatin impairs activation of FAK and phosphorylation of its
Y118 target site in paxillin (Figure 4d), thus conﬁrming previous
reports that FAK activation is dispensable for cell spreading in this
context.25,26 These results indicate that Rho, via actin-myosin
contractility, inhibits a Crk-p130Cas-DOCK5-Rac1 signaling path-
way to suppress lamellipodial protrusion.
Unbiased biochemical analysis has established that GIT2 is a
highly tension-dependent FA constituent.27 Accordingly, endo-
genous GIT2 localizes to mature FAs, consistent with a
Figure 1. GIT2 represses DOCK5-regulated and Rac1-dependent cell spreading, as well as FA turnover. HeLa cells were transfected with the
indicated shRNA expression vectors and selected in 2.5 μg/ml of puromycin for 72 h. Cells were then cultured for an additional 24 h in the
absence of puromycin. (a) Phase contrast images of control, GIT2-kd, DOCK1-kd, DOCK5-kd and GIT2-kd+DOCK5-kd cells cultured on collagen.
(b) Quantiﬁcation of cell area occupied by control, GIT2-kd, DOCK5-kd and GIT2-kd+DOCK5-kd HeLa cells 1 h after plating on collagen.
(c) Control and DOCK5-kd cells were plated on collagen and assayed for adhesion after 1 h. All values are means± s.d. (n = 3).
(d) Quantiﬁcation of the distribution of areas occupied by control, GIT2-kd, GIT2-kd+Rac1-kd and GIT2-kd+Rac3-kd HeLa cells 1 h after plating
on collagen. (e) Speciﬁcity of NewEast Biosciences antibody for Rac-GTP. Recombinant Rac1 was loaded with either GDP or GTPγS followed by
immunoprecipitation with monoclonal antibody to Rac1-GTP and western blotting. (f) Localization of Rac-GTP in control, GIT2-kd, DOCK5-kd
and GIT2-kd+DOCK5-kd cells 1 h after plating on collagen. (g) FA turnover in live HeLa cells expressing paxillin-GFP. Representative confocal
images illustrate FA formation over times indicated in control, GIT2-kd, DOCK5-kd and GIT2+DOCK5-kd cells grown on glass. (h) Rate (min− 1)
of assembly, disassembly and turnover of FAs as measured by change in GFP ﬂuorescence over time for control, GIT2-kd, DOCK5-kd and GIT2
+DOCK5-kd Hela cells, ***Po0.001, **Po0.002, analysis of variance with Tukey–Kramer post hoc testing.
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requirement for RhoA in its targeting.19 Nevertheless, it has been
reported that GIT2 is recruited in a Rac- and not Rho-dependent
manner to nascent adhesions.28 To address this conundrum,
we treated HeLa cells with blebbistatin for 20 min to initiate
FA disassembly. Blebbistatin causes a rapid loss of GIT2 from
FAs, preceding complete redistribution of paxillin (Figure 5a).
Pharmacological inhibition of ROCKs with the small molecule
Y27632 also elicits a rapid loss of GIT2 from FAs (Figure 5a).
We additionally tested the effect of Rac interference on GIT2
localization. HeLa cells express Rac1 and Rac3, which we depleted
separately or together (Figure 5b). Knockdown of Rac1 and/or
Rac3 did not prevent GIT2 targeting to FAs (Figures 5c and c’).
Taken together, our results support a model whereby recruitment
of GIT2 to FAs is promoted by Rho-dependent cystokeletal tension
and leads to suppression of DOCK5, thus suggesting a novel
mechanism for Rho to antagonize the function of Rac.
GIT2 and DOCK5 control mammary epithelial cell motility and
invasiveness
We previously showed that the loss of GIT2 greatly enhances the
invasiveness of non-transformed mammary MCF10A cells.19 To assess
Figure 2. GIT2 modulates a Crk-p130Cas-DOCK5 signaling pathway required cell spreading. (a) Puromycin selected control, GIT2-kd, DOCK5-
kd or DOCK5 and GIT2-kd cells were plated on collagen-coated plates for 2.5 h. Next, whole-cell lysates were processed for western blotting to
detect GIT2, DOCK1, DOCK5 and ERK as loading control, as well as phosphorylated forms and total levels of p130Cas, FAK and paxillin.
(b) Quantiﬁcation of phospho-p130Cas, -paxillin, and -FAK levels from a. All values are means± s.d. (n= 3). *Po0.05; **Po0.02; ***Po0.01 by
unpaired two-tailed Student's t-test. (c) DOCK5 binds to Crk in a GIT2-regulated manner. HeLa cells with or without GIT2 depletion were plated
on collagen-coated plates for 2.5 h. The cells were then lysed and the samples processed for immunoprecipitation with anti-Crk antibody and
western blotting to detect Crk, p130Cas and Crk in immunoprecipitates and whole-cell lysates. (d) Quantiﬁcation of the amount of DOCK5
associated with Crk in control and GIT2-kd cells. Values are means± s.d. (n= 3). ***Po0.01 by unpaired two-tailed Student's t-test. (e) Cells
with or without knockdown of GIT2 were transfected overnight with a Myc-tagged form of the CBD of DOCK5 comprises amino acids
1712–1871. Transfected cells were plated on collagen for 1 h and labeled to detect Myc (green) and Arp3 (red). (f) Quantiﬁcation of cell area
from e. All values are means± s.d. (n = 3). ***Po0.01 by unpaired two-tailed Student's t-test.
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the role of DOCK5 in cell migration, we localized DOCK5 in wounded
MCF10A cell monolayers. Endogenous DOCK5 is rapidly recruited to
the wound edge, where it colocalizes with paxillin, Arp3, and cortactin
(Figure 6a). Stable DOCK5 depletion markedly reduces wound
healing, indicating that DOCK5 is required for regulated motility
(Supplementary Figure S3a). Next, we used a previously described
method for inducible knockdown to target GIT2 and DOCK5 in
MCF10A cells (Figure 6b).29 Knockdown of GIT2 increases migration
through Matrigel-coated invasion chambers when epidermal growth
factor (EGF) is provided as a chemoattractant (Figure 6c). Enhanced
invasiveness observed in GIT2-kd cells is entirely dependent on
DOCK5 (Figure 6c), indicating that GIT2 serves as an essential
repressor of DOCK5 in this context.
DOCK1 functions downstream of EGF receptors ErbB-2
(a.k.a HER2) to mediate invasion and metastasis of mammary
carcinoma cells.30 We used small interfering RNA (siRNA)-
mediated gene knockdown to target DOCK1 and DOCK5 in the
highly invasive mammary carcinoma cell line MDA-MB-231
(Figure 6d). Consistent with observations in the mammary
carcinoma cell line T47D,30 knockdown of DOCK1 impairs
invasiveness of MDA-MB-231 cells in response to EGF
(Supplementary Figure S3b). DOCK5 depletion also reduces
invasiveness signiﬁcantly, revealing a previously unanticipated
role for DOCK5 in this process (Supplementary Figure S3b).
Interestingly, although MDA-MB-231 cells appeared slightly more
dependent on DOCK1 than DOCK5 for EGF-dependent invasion,
the reverse is true when serum is used as a chemoattractant
(Figure 6e and Supplementary Figure S3c). These results were
validated with an additional three siRNAs targeting DOCK5
(Supplementary Figures S3d and e). Similar to MCF10A and HeLa
cells, DOCK5 localizes to the protrusive edge of migrating MDA-
MB-231 cells, whereas its loss impairs lamellipodial protrusion
(Figure 6f). Moreover, depletion of DOCK5 from MDA-MB-231 cells
markedly reduces phosphorylation of p130Cas, paxillin, and
Figure 3. DOCK5 localization is controlled by GIT2. (a) Localization of DOCK1 (green) or DOCK5 (green) together with paxillin (red) in HeLa
cells transfected with DOCK1 or DOCK5 expression constructs. (b) Localization of DOCK5 (green) and paxillin (red) in control and
GIT2-depleted cells transfected with DOCK5 expression construct and plated on collagen for 1 h. (c) HeLa cells were transfected with control,
GIT2, and DOCK5 shRNA expression vectors and selected in puromycin as described in Figure 1. Pooled knockdown cells were plated on
collagen for 1 h and labeled to detect DOCK5 (green) and paxillin (red). (d) Pooled knockdown cells plated on collagen for 1 h were labeled to
detect DOCK5 (green) and Arp3 (red). All scale bars represent 10 μm each.
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FAK (Figures 6g and h). Finally, we performed invasion assays with
MDA-MB-231 cells overexpressing wild-type DOCK5 or catalytically
inactive DOCK5(ISP). In contrast to wild-type DOCK5, overexpres-
sion of DOCK5(ISP) yielded a ~ 50% inhibition of invasion
(Figure 6i). This result shows a role for enzymatic activity of
DOCK5 to promote mammary carcinoma cell invasion.
DOCK5 promotes metastasis of mammary carcinoma cells
To test a requirement for DOCK5 in invasiveness in vivo, we
performed tail vein injection experiments with MDA-MB-231 cells
in nude mice. Cohorts of mice were injected with either control
cells, a pool of DOCK5-kd cells, or clonal cell populations with
DOCK5-kd (Figure 7a). Four weeks later (day 28), the mice injected
with control cells were killed because of respiratory distress
(Supplementary Table S1). In contrast, all mice injected with
DOCK5-depleted cells were viable and without external signs of
disease with exception of one mouse that was killed because of an
unrelated liver abnormality. At this time (day 28), three mice
injected with a pool of DOCK5-depleted cells, as well as one
mouse from each of the DOCK5-kd clones, were killed for
histological analysis.
Lungs harvested from mice injected with control MDA-MB-231
cells exhibited major increases in size and weight compared with
lungs from mice injected with DOCK5-kd cells (Figures 7b and c).
The lungs from mice injected with control cells were compacted
with tumor cells (Figure 7d and Supplementary Figure S4a).
In contrast, lungs from mice injected with a pool of DOCK5-kd
cells contained numerous discrete tumors dispersed within
normal lung tissue, whereas much smaller tumors were detected
in lungs from mice injected with clonal populations of DOCK5-kd
cells (Figure 7d and Supplementary Figure S4a). The remaining
mice in the study were subsequently monitored and terminated
upon of signs of disease (Supplementary Table S1). The results are
shown in the Kaplan–Meier plot in Figure 7e. Mice injected with a
pool of DOCK5-kd cells lived signiﬁcantly longer than controls, but
shorter than mice injected with clonal populations of DOCK5-kd
cells (Figure 7f). Survival correlated with the efﬁciency of DOCK5-
kd (Figure 7a). Collectively, these results establish that DOCK5
promotes metastasis of MDA-MB-231 cells.
To quantify the effect of DOCK5 depletion on tumor burden,
we performed a shorter experiment where all mice were
terminated on day 21, before any external signs of disease. Lungs
Figure 4. Activity of DOCK5 is repressed by myosin II contractility. (a) HeLa cells were transfected with control or DOCK5 shRNA expression
vectors and cultured in puromycin to select for expression of the resistance marker present in the vector. Cells were treated with the myosin II
inhibitor blebbistatin (50 μM) or vehicle for 12 h and examined by phase contrast microscopy. (b) Localization of DOCK5 (green) and paxillin
(red) in control and DOCK5-kd cells treated with blebbistatin for the indicated times. Scale bar indicates 10 μm. (c) Control cells treated with
blebbistatin for 0 or 4 h were labeled to detect DOCK5 (green) and Arp3 (red). Scale bar represents 10 μm. (d) Western blot analysis of control
and DOCK5-knockdown cells treated with blebbistatin for 0, 1, 2 and 4 h to detect phosphorylated forms and total levels of p130Cas, paxillin
and FAK.
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for these mice were processed for stereological analysis
(Supplementary Figure S4b). Select sections were moreover
stained with antibody speciﬁc for human cytokeratin to conﬁrm
that tumor elements were indeed comprised of MDA-MB-231 cells
(Figure 8a). Quantiﬁcation revealed that DOCK5-kd elicits a
signiﬁcant decrease in tumor burden from 40% in mice injected
with control MDA-MB-231 cells to 7% in mice injected with a
pooled population of DOCK5-depleted cells and 2–4% in mice
injected with clones of DOCK5-deﬁcient cells (Figures 8a and b).
The differences in tumor burden between mice injected with
Figure 5. Activity of myosin II is required for localization of GIT2 to FAs. (a) HeLa cells were treated for 20 min with vehicle, blebbistatin (50 μM)
or Y27632 (10 μM). Cells were labeled to detect GIT2 (green) or paxillin (red). Scale bar indicates 10 μm. (b) Hela cells were transfected with
control, Rac1, Rac3, or Rac1 and Rac3 siRNA. Cells were lysed 48 h post-transfection and whole-cell lysates were immunoblotted with
antibodies speciﬁc for Rac1, Rac3 and ERK. (c) HeLa cells depleted of Rac1, Rac3, or Rac1 and Rac3 were labeled to detect paxillin (green) and
GIT2 (red). Insets in panel (c’), highlight areas of colocalization between GIT2 and paxillin. Scale bar represents 10 μm.
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Figure 6. DOCK5 is required for mammary epithelial cell invasion and wound repair. (a) MCF10A cells were cultured on ﬁbronectin. Cell
monolayers were labeled to detect DOCK5 (green) and Arp3, cortactin or paxillin (red) 6 h after wounding. Scale bar indicates 20 μm.
(b) MCF10A cells selected to conditionally express control, GIT2, or GIT2 and DOCK5 shRNA were treated with doxcycline for 72 h. Lysates
were immunoblotted to detect GIT2, DOCK5, DOCK1 and ERK. (c) To quantify changes in MCF10A invasion, control (black), GIT2-kd (red), or
GIT2+DOCK5-kd (blue) cells were harvested and added to the top chamber of Matrigel-coated transwell ﬁlters and incubated for 12 h in the
presence of 10 ng/ml of EGF as a chemoattractant. Cells that migrated to the bottom chamber were quantiﬁed. Values are means± s.d. (n= 3).
(d) MDA-MB-231 cells transiently transfected with siRNA targeting DOCK5 and DOCK1 were lysed and immunoblotted. (e) siRNA control
(black), DOCK5-kd (red) and DOCK1-kd (blue) MDA-MB-231 cells were assayed for invasion through Matrigel-coated ﬁlters in the presence of
10% serum as a chemoattractant. Values are means ± s.d. (n= 3). (f) Immunolocalization of DOCK5 (green) and Arp3 (red) in MDA-MB-231
control and DOCK5-kd cells. Scale bar represents 10 μM. (g) Whole-cell lysates of MDA-MB-231 cells were processed for western blotting to
detect GIT2, DOCK1, DOCK5 and ERK as loading control, as well at phosphorylated forms and total levels of p190Cas, FAK and paxillin.
(h) Quantiﬁcation of phospho-p130Cas, -paxillin and -FAK levels from g. (i) MDA-MB-231 cells stably transduced with empty lentiviral vector
(control), lentiviral expression constructs encoding wild-type DOCK5 or catalytically inactive DOCK5(ISP) were assayed for invasion through
Matrigel-coated ﬁlters in the presence of 10% serum as a chemoattractant. All values in this ﬁgure are means± s.d. from a minimum of n = 3 or
more experiments. *Po0.05; **Po0.02; ***Po0.01 by unpaired two-tailed Student's t-test.
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control and DOCK5-kd cells does not appear to result from effects
on cell proliferation or cell adhesion (Figures 8c and d). In contrast,
formation of membrane rufﬂes was attenuated in the pool of
DOCK5-kd cells and virtually abolished in the clonal DOCK5-kd cell
lines (Figure 8e). The latter ﬁnding is consistent with the
conclusion that reduced tumor burden in mice injected with
DOCK5-kd cells results from diminished motile and invasive
capacities.
Finally, expression analysis of HER2 mouse breast tumors
identiﬁed DOCK1, DOCK5, DOCK6 and DOCK7 among the most
abundantly expressed Rho GEFs, indicating that multiple DOCK
members may have a role in capacities associated with oncogenic
cell transformation.30 We probed human breast cancer cell protein
arrays and found that DOCK5 was widely expressed
(Supplementary Figure S5). However, we found no consistent
differences in expression between tumor sample and matched
adjacent normal tissue. Thus, any changes in DOCK5 function in
human cancer are more likely the result of modulated activity, as
opposed to increased expression.
DISCUSSION
DOCK family members are emerging as pivotal regulators of
cellular processes involving adhesion and the actin cytoskeleton.
Here we identify DOCK5 as an essential regulator of epithelial
motility and invasiveness. Moreover, in an animal model of
metastasis, inhibition of DOCK5 reduces tumor burden and
signiﬁcantly increases survival time. DOCK5 and DOCK1 are co-
expressed in numerous cell types. Our results indicate that DOCK1
and DOCK5 function in a non-redundant manner to modulate
serum- and EGF-dependent invasiveness.
DOCK1 and DOCK5 contribute to the generation of distinct
actin structures. Here we demonstrate that DOCK5 mediates
peripheral actin polymerization and membrane protrusion via
activation of a Crk-p130Cas-DOCK5 signaling cascade. This
cascade is suppressed by GIT2, as depletion of GIT2 results in
deregulated lamellipodial protrusions that depends on the activity
of DOCK5 but not DOCK1. The non-redundant functions of DOCK1
and DOCK5 in epithelial invasion may result from an ability to
Figure 7. DOCK5 is required for metastasis of MDA-MB-231 cells. (a) Western blot analysis was used to determine DOCK5 levels in MDA-
MB-231 cell lines. MDA-MB-231 cells were retrovirally transduced with either control or DOCK5 shRNA expression vectors. A pooled
population of DOCK5-kd cells and two independent clonal DOCK5-kd cell lines were generated. (b) Representative pictures of lungs from mice
killed 28 days after intravenous injection of control or DOCK5-knockdown (clone A) cell lines. (c) Average lung weights of control (12 mice),
pool (3 mice), clone A (1 mouse) and clone B (1 mouse) injected mice killed on day 28. Values are means± s.d. ***Po0.02 by unpaired two-
tailed Student's t-test. (d) Hematoxylin and eosin staining of lungs harvested on day 28 from mice intravenously injected with the indicated
cell lines. Arrows mark the perimeter of scattered extravascular tumors present in mice injected with pooled, clone A and clone B DOCK5-kd
cells. Scale bar indicates 100 μM. (e) Kaplan–Meier survival plots representing results of intravenous tail vein injection of MDA-MB-231 vector
control cells, as well as DOCK5 shRNA-expressing pool and clonal cell populations. Median overall survival: control (28 days; n= 12 mice), pool
(44 days; 7 mice), clone A (52 days; 7 mice) and clone B (58.7 days; 7 mice). (f) P-values calculated with a log-rank test and resulting from the
pairwise comparison of survival times for the designated mouse cohorts.
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regulate distinct actin structures. Although both DOCK1 and
DOCK5 are present in peripheral rufﬂes, DOCK1 possesses a
unique C-terminal motif that binds phosphatidic acid and
mediates its recruitment to dorsal rufﬂes.31 As a result, loss of
DOCK1, but not DOCK5, impairs dorsal rufﬂe formation.31 Dorsal
rufﬂes seem important for migration through 3D environments.32
Therefore, assembly of distinct DOCK1- and DOCK5-dependent
actin structures may be required for optimal cell invasiveness.
DOCK1 and DOCK5 also form heterodimers, which appears
essential for their in vivo biological function, offering an additional
mechanism for non-redundancy in their function.33–35
Here, we establish that GIT2 represses the activity of DOCK5 but
not DOCK1. GIT2 localizes to FAs via its association with the
scaffolding protein paxillin.36 Our past and present observations
indicate that active Rho, via a ROCK- and myosin II-dependent
pathway, triggers the recruitment of GIT2 to nascent adhesions.
This conclusion is supported by a comprehensive proteomic
analysis of ﬁbroblasts, which ranked GIT2 as among the top
myosin II-dependent FA components.27 Our data suggest that
GIT2 is rapidly targeted to nascent adhesions in response to Rho-
initiated cytoskeletal tension, where it promotes transition from
nascent DOCK5- and Rac-dependent protrusive adhesions to
mature Rho-dependent contractile adhesions. In this context, we
identify GIT2 as a novel mediator of Rho-Rac antagonism in
control of motile and invasive capacities.
Our results suggest that oncogenic signaling, which inhibits
GIT2 or activates DOCK5, will promote metastasis. Others have
designed DOCK inhibitors, although none effectively distinguish
between individual DOCK-A group members.13,37 As DOCK5 is
largely dispensable for gross embryonic development, our results
indicate that DOCK5 is speciﬁcally required for wound repair and
cell invasion. As such, DOCK5 may be part of a tumor-speciﬁc
Figure 8. DOCK5-regulated metastasis of MDA-MB-231 is mediated through effects on motile/invasive capacities. (a) Representative images of
tumor burden in lungs of nude mice 21 days after injection with control, DOCK5-kd pool, DOCK5-kd clone A and DOCK5-kd clone B cells. Scale
bar represents 500 μm. The insets show adjacent sections of a small tumor stained with hematoxylin and eosin and human cytokeratin,
respectively. Scale bar represents 50 μm. (b) Quantiﬁcation of tumor burden in these mouse cohorts as described in Materials and methods
(n= 4 mice in each cohort). **Po0.02 by unpaired two-tailed Student's t-test. (c) Cell proliferation rates in control, DOCK5-kd pool, DOCK5-kd
clone A, and DOCK5-kd clone B MDA-MB-231 cells (n= 3). (d) Quantiﬁcation of cell adhesion, as performed in Figure 1c using 40 μg/ml of
collagen, in control, DOCK5-kd pool, DOCK5-kd clone A, and DOCK5-kd clone B MDA-MB-231 cells (n= 3). (e) Morphology of control,
DOCK5-kd pool, DOCK5-kd clone A and DOCK5-kd clone B MDA-MB-231 cells after overnight plating on collagen. The fraction of cells with
membrane rufﬂes ⩾ 30 μm in length was quantiﬁed from 125 cells from each condition.
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invasion pathway (Figure 9). It will be important for future studies
to assess whether DOCK5 has a role in other integrin-dependent
processes required for metastasis such as anchorage-independent
growth, matrix degradation and cell extravasation.
MATERIALS AND METHODS
DOCK5 and DOCK1 mammalian expression vectors
Full-length human DOCK5 complementary DNA (cDNA; identical to
NM_024940) was assembled in pCMV-Myc (Clontech/Takara, Mountain
View, CA, USA) from partial cDNAs provided by NITE (www.nbrc.nite.go.jp)
and RZPD (www.imagenes-bio.re). This DOCK5 cDNA was transferred to
pLenti-puro (Addgene, Cambridge, MA, USA) for lentiviral transduction.
DOCK1 expression vector was kindly provided by Kodi Ravichandran. An
expression vector encoding the DOCK5 CBD (amino acids 1712–1871) was
generated in pCMV-Myc.
Generation of DOCK5-speciﬁc antibody
DOCK5 cDNA encoding amino acids 1712–1871 and DOCK1 cDNA encoding
amino acids 1691–1866 were inserted into pGEX-4T-1 (GE Healthcare Life
Sciences, Pittsburgh, PA, USA). Recombinant GST-DOCK5-CT was used to
generate antiserum reactive with DOCK5. Antibodies cross-reactive with
DOCK1 or GST were removed by incubation with GST-DOCK1-CT coupled to
glutathione sepharose followed by centrifugation. The supernatant containing
DOCK5-speciﬁc antibody was used for experimentation.
Vector-based shRNA
To generate shRNAs for DOCK5, complimentary 80–87 oligonucleotides
were annealed and cloned into pReSI-Puro, pReSI-Hygro or pReSI-GFP
retroviral vectors as previously described.19 The target sequence of
validated GIT2 shRNA was previously described.19 The target sequence
of the primary DOCK5 shRNA (sense–antisense) was the following: 5′-
GATCCCGAGCAGATCTTAAACTACTACGCCCGGGCCGCCCTGTAGTAGTTTAA-
GATCTGCTCTTTTTTGGAACTCGAGA-3′.
Additional DOCK5 shRNA sequences used in Supplementary Figure S2
were as follows: shRNA-1: 5′-GATCCCGAAGTACCTTCCTAGCATAATGCCC
GGGCCGCCCTATTATGCTAGGAAGGTACTTCTTTTTTGGAACTCGAGA-3′; shRNA-
-2: 5′-GATCCCGGACCTGATTGGAAAGAATGTGCCCGGGCCGCCCTACATTCTTTC
CAATCAGGTCCTTTTTTGGAACTCGAGA-3′; shRNA-3: 5′-GATCCCGAGAAGCTGT
ATCAAGAAATCGCCCGGGCCGCCCTGATTTCTTGATACAGCTTCTCTTTTTTGGAA-
CTCGAGA-3′; shRNA-4: 5′-GATCCCGAATGTCTATGCCAAAGATTGGCCCGGGC
CGCCCTCAATCTTTGGCATAGACATTCTTTTTTGGAACTCGAGA-3′.
Cell spreading and adhesion assay
For stable knockdown of DOCK5 in HeLa cells (Supplementary Figure S2),
retrovirus was used to transduce cells with pReSI-Hygro vector encoding
four distinct shRNA-targeting sequences and selected in the presence of
hygromycin. For transient shRNA-mediated knockdown, HeLa cells were
transfected with shRNA expression constructs as previously detailed.19
Next, cells were plated onto collagen-coated coverslips. To determine the
requirement for DOCK1 and DOCK5 in GIT2-regulated cell spreading
(Supplementary Figure S1), HeLa cells were transfected with 50 nM of
siRNA duplexes targeting DOCK1 (Ambion ID# 145822; GE Healthcare Life
Sciences) or DOCK5 (Ambion ID# 130801) using LipofectAmine 2000.
To quantify effects on cell adhesion, non-enzymatically harvested
control or DOCK5 shRNA-expressing cell populations were resuspended
in Dulbecco’s modiﬁed Eagle’s medium (supplemented with 10 mM HEPES
pH 7.4 and 0.5% bovine serum albumin) and plated onto collagen-coated
96-well plates (50 000 cells per well). After 90-min incubation at 37 °C, wells
were rinsed in phosphate-buffered saline+ and adherent cells quantiﬁed
using the CyQuant cell proliferation assay kit (Molecular Probes; Thermo
Fisher Scientiﬁc, Waltham, MA, USA).
Live cell imaging of HeLa cells expressing paxillin-GFP
A paxillin-GFP expression construct was generated in pLenti-Puro. HeLa
cells expressing paxillin-GFP were selected with puromycin. Paxillin-GFP
expressing cells were grown on 15 mm2 glass coverslips and GIT2 and/or
DOCK5 expression was depleted as detailed above. The coverslips were
mounted in a custom-imaging chamber maintained at 37 °C and pH 7.4
throughout the observation period. Analysis of FA assembly, disassembly
and turnover rates was performed essentially as described by Webb et al.24
Immunoﬂuorescence microscopy, immunoprecipitation and
western blotting
Cells were ﬁxed in methanol/acetone (1:1) with exception of samples
processed for Rac-GTP labeling, which were ﬁxed in 2% formalin and
permeabilized with 0.1% Triton X-100. Processing of samples was carried out as
described previously.19 Antibodies used for immunoﬂuorescence were: rabbit
anti-GIT2;19 rabbit anti-DOCK5 (described above); rabbit anti-DOCK1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA, clone H-70); mouse
anti-paxillin (BD Biosciences, San Jose, CA, USA, clone 349), mouse anti-ARP3
(Sigma, St Louis, MO, USA, clone FMS338); mouse anti-Rac-GTP (NewEast
Biosciences, Malvern, PA, USA, clone 26903); and mouse anti-Myc epitope
(Cell Signaling Technologies, Danvers, MA, USA, clone 9B11). Confocal images
were acquired using a spinning disk confocal microscope.
Antibodies used for immunoprecipitation and western blotting were: mouse
anti-Crk (BD Biosciences; clone 22); rabbit anti-Crk (Santa Cruz Biotechnology;
C-20), mouse anti-DOCK1 (Santa Cruz Biotechnology; clone H-4), mouse
anti-p130Cas (BD Biosciences; clone 21), mouse anti-Rac1 (BD Biosciences;
clone 102), rabbit anti-Rac3 (Abcam; clone EPR6680), rabbit anti-FAK
(Santa Cruz Biotechnology; clone A-17), rabbit anti-phospho-p130Cas(Tyr410),
rabbit anti-phospho-paxillin(Tyr118) and rabbit anti-phospho-FAK(Tyr397).
All phospho-speciﬁc antibodies were from Cell Signaling Technologies.
MCF10A cell invasion assay
To generate cell lines with inducible knockdown of GIT2, MCF10A-TetR
cells were retrovirally transduced with pReSI-Puro or pReSI-Puro-GIT2
shRNA and selected in puromycin. A clone exhibiting inducible GIT2
knockdown was subsequently transduced with pReSI-Hygro-DOCK5 and
selected in hygromycin. To induce knockdown of GIT2 and/or DOCK5, cells
were treated with 4 μg/ml of doxycyline for 72 h. Next, 1 × 105 cells
were plated into the top chamber of a Matrigel invasion chamber
(BD Biosciences). Cells were allowed to migrate overnight using 10 ng/ml
of EGF in Dulbecco’s modiﬁed Eagle’s medium/F12 as chemoattractant.
Migrated cells were quantiﬁed using CyQuant (see above).
MDA-MB-231 cell invasion assay
MDA-MB-231 were transfected with SMARTpool siRNA (siGeNOME, Dharma-
con, Lafayette, CO, USA), targeting DOCK1 or DOCK5 (ﬁnal concentration
50 nM), using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA).
Figure 9. Cartoon illustrating a novel signaling pathway for the
coordinated regulation of Rho and Rac signaling in epithelial
invasion. In this pathway, Rho-dependent activation of ROCK targets
GIT2 to FAs, where GIT2 suppresses the activity of a Crk-p130Cas-
DOCK5 signaling pathway required for activation of Rac and
mammary epithelial cell invasion. The Crk-p130Cas-DOCK5 signaling
pathway has non-redundant and essential role in epithelial invasion
and metastasis, underscoring the need for tight regulation of this
pathway by GIT2 in non-transformed cells.
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Additional siRNA duplexes targeting DOCK5 with sequences as follows were
custom ordered from Dharmacon: siRNA-1: 5′-GAGGAUGACUGCAA
AGAAAUU-3′; siRNA-2: 5′-GGAGAGAACUCAAGCUGUAUU-3′; siRNA-3: 5′-UU
UCAAACAUGGACAGUUAUU-3′.
Seventy-two hours post-transfection, cells were trypsinized and 1× 105
cells were plated into the top well of a Matrigel-coated invasion chambers
and incubated for 12 h. Assays were conducted using Dulbecco’s modiﬁed
Eagle’s medium supplemented with either 10% serum or 10 ng/ml of EGF
as a chemoattractant. Migrated cells were ﬁxed in 4% formaldehyde,
stained with crystal violet and counted.
Tail vein injection of MDA-MB-231 cells
Animal modeling of the metastatic potential of control and DOCK5-
knockdown MDA-MB-231 cell lines was carried out by Pipeline Biotech
A/S (Trige, Denmark). Pipeline Biotech was blinded to the identity of the
individual cell lines. All animal experiments were performed according to
standards set by the Animal Experiments Inspectorate in Denmark. Brieﬂy,
CB-17 female SCID mice were injected with 100 μl phosphate-buffered
saline containing 1 × 106 cells in the tail vein. The injected mice were
maintained under identical conditions and were monitored regularly.
End point assays were conducted when signiﬁcant morbidity required that
the mouse be euthanized (see Supplementary Table S1 for details).
Following killing, the thorax and abdomen of mice were opened and
internal organs inspected for gross pathological analysis and lungs were
evacuated and ﬁxed by immersion in 4% formalin for 24 h followed by
parafﬁn embedding and processed for histology as described below.
Histology
Parafﬁn-embedded lungs were cut into 1.5 mm slabs from apex to base.
The slabs were mounted side-by-side and cut into 5 μm section that were
deparafﬁnized and rehydrated before hematoxylin and eosin staining or
histochemistry. Detection of human cytokeratin was carried out using
AE1/AE3 clone M3515 (Dako, Glostrup, Denmark) by standard procedures.
A NanoZoomer-2.0HT (Hamamatsu, Hamamatsu City, Shizuoka Pref., Japan)
was used to scan entire sections. Lung metastasis volume was quantiﬁed
blinded using a computer-assisted stereological technique using the
Visiopharm stereology software package and the newCAST stereology
module (Visiopharm, Hørsholm, Denmark).38
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